Acute pancreatitis (AP) Industry Segmentation, Trends and Global Briefing 2019

Acute pancreatitis (AP) is a systemic immunoinflammatory response to auto-digestion of the pancreas and peri-pancreatic organs.The mortality rate for pancreatitis is between 1.5% and 4.2% according to large epidemiological studies but is a frequent gastrointestinal disease with a morbidity rate of 30% in severe cases.

Acute pancreatitis is confirmed by medical history, physical examination, and typically a blood test (amylase or lipase) for digestive enzymes of the pancreas. The diagnosis of pancreatic is often difficult and treatments are therefore delayed because the organ is relatively inaccessible.

Avail Free Sample Copy Enabled with Complete TOC at https://www.marketresearchfuture.com/sample_request/1565

The testing of acute pancreatits include techniques such as transabdominal ultrasound, endoscopic ultrasound (EUS), and magnetic resonance cholangiopancreatography (MRCP). Surgery has no role in mild acute pancreatitis or in severe pancreatitis with sterile necrosis. Surgical therapy in infected necrosis can be considered, based on the availability of other therapeutic options and the consistency of the necrotic material.

The global acute pancreatitis market is expected to grow at a CAGR of 3.5% during forecasted period 2017-2023.

1. Abbott Laboratories (US)

2. McNeil Consumer Healthcare (US)

3. Sun BioPharma Inc (US)

4. Atox Bio Inc. (Israel)

5. Calcimedica Inc. (US)

6. D-Pharm Ltd (Israel)

7. Dynavax Technologies Corporation (US)

8. Glaxosmithkline Plc (UK) university’s and institutes

According to the 2013 American College of Gastroenterology (ACG) guidelines, antibiotics are usually not recommended in patients with acute pancreatitis, regardless of the type or disease severity. Infection must be suspected in patients who have signs of deterioration such as fever, increasing WBC count. Most infections in pancreatic necrosis are caused by single bacterial species from the gut. In patients with infected necrosis, antibiotics known to penetrate pancreatic necrosis, such as carbapenems, fluoroquinolones, and metronidazole, are recommended. Byetta (exanitide) is a drug from Eli Lily and Company that is FDA approved to treat acute pancreatitis.

Acute pancreatitis Market Segments:

Global Acute Pancreatitis market has been segmented on the basis of types of testing which comprises of Transabdominal ultrasound, Endoscopic ultrasound (EUS), Magnetic resonance cholangiopancreatography (MRCP), Computerized tomography (CT) and others On the basis of type of treatment which consists of Fluids, Nutritional Support, Treatment of Underlying Issues, Endoscopic Retrograde Cholangiopancreatography (ERCP) and others. On the basis of type of therapy which consists of Massage Therapy, Therapeutic Touch, Acupuncture and others